Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study

References

• Parving H‐H., Andersen A. R., Smidt U. M., Svendsen P. Aa. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; i: 1175–9
   Google Scholar
• Gaede P., Vedel P., Parving H‐H., Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617–22
   PubMed Web of Science ®Google Scholar
• Gall M‐A., Hougaard P., Borch‐Johnsen K., Parving H‐H. Risk factors for development of incipient and overt diabetic nephropathy in patients with non‐insulin dependent diabetes mellitus: prospective, observational study. Br Med J 1997; 314: 783–8
   PubMed Web of Science ®Google Scholar
• Caramori M. L., Fioretto P., Mauer M. Enhancing the predictive value of urinary albumin for diabetic nephropathy. J Am Soc Nephrol 2006; 17: 339–52
   PubMed Web of Science ®Google Scholar
• Yishak A. A., Costacou T., Virella G., Zgibor J., Fried L., Walsh M., et al. Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of Diabetes Complications cohort. Nephrol Dialysis Transpl 2006; 21: 93–100
   PubMed Web of Science ®Google Scholar
• Diamond J. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int 1991; 39: S‐29–S‐34
   Web of Science ®Google Scholar
• Ridker P. M., Hennekens C. H., Roitman‐Johnson B., Stampfer M. J., Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88–92
   PubMed Web of Science ®Google Scholar
• Ridker P. M. M., Rifai N. M., Stampfer M. J. M., Hennekens C. H. M. Plasma concentration of Interleukin‐6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767–72
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Rifai N., Rose L., Buring J. E., Cook N. R. Comparison of C‐reactive protein and low‐density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557–65
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Rifai N., Pfeffer M., Sacks F., Lepage S., Braunwald E. Elevation of tumor necrosis factor‐alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149–53
   PubMed Web of Science ®Google Scholar
• Stehouwer C. D., Gall M. A., Twisk J. W., Knudsen E., Emeis J. J., Parving H‐H. Increased urinary albumin excretion, endothelial dysfunction, and chronic low‐grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diab 2002; 51: 1157–65
   PubMed Web of Science ®Google Scholar
• Parving H‐H., Lehnert H., Bröchner‐Mortensen J., Gomis R., Andersen S., Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8
   PubMed Web of Science ®Google Scholar
• Hofman W., Guder W. Preanalytical and analytical factors involved in the determination of urinary Immunoglobin G, albumin, alpha 1‐microglobin and retinol binding protein using the Behring nephelometer system. Lab Med 1989; 13: 470–8
   Google Scholar
• Seelig H. P. The Jaffe reaction with creatinine. Reaction product and general reaction conditions. Z Klin Chem Klin Biochem 1969; 7: 581–5
   PubMedGoogle Scholar
• Goldstein D. E., Little R. R., Wiedmeyer H. M., England J. D., McKenzie E. M. Glycated hemoglobin: methodologies and clinical applications. Clin Chem 1986; 32: B64–B70
   PubMed Web of Science ®Google Scholar
• Stehouwer C. D. A., Nauta J. J. P., Zeldenrust G. C., Hackeng W. H. L., Donker A. J. M., den Ottolander G. J. H. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non‐insulin‐dependent diabetes mellitus. Lancet 1992; 340((ii))319–23
   PubMedGoogle Scholar
• Jager A., van Hinsbergh V. W., Kostense P. J., Emeis J. J., Nijpels G., Dekker J. M., et al. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study. Diab 2000; 49: 485–91
   PubMed Web of Science ®Google Scholar
• Jager J., Kooy A., Lehert P., Bets D., Wulffele M. G., Teerlink T., et al. Effects of short‐term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo‐controlled trial. J Intern Med 2005; 257: 100–9
   PubMed Web of Science ®Google Scholar
• Wrobel K., Wrobel K., Garay‐Sevilla M., Nava L. E., Malacara J. M. Novel analytical approach to monitoring advanced glycosylation end products in human serum with on‐line spectrophotometric and spectrofluorometric detection in a flow system. Clin Chem 1997; 43: 1563–9
   PubMed Web of Science ®Google Scholar
• Schram M. T., Chaturvedi N., Schalkwijk C. G., Fuller J. H., Stehouwer C. D. A. Markers of inflammation are cross‐sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes. The EURODIAB Prospective Complications Study. Diabetologia 2005; 48: 370–8
   PubMed Web of Science ®Google Scholar
• Jager A., van Hinsbergh V. W. M., Kostense P. J., Emeis J. J., Nijpels G., Dekker J. M., et al. C‐reactive protein and soluble vascular cell adhesion molecule‐1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler Thromb Vasc Biol 2002; 22: 593–8
   PubMed Web of Science ®Google Scholar
• Persson F., Rossing P., Hovind P., Stehouwer C. D., Schalkwijk C., Tarnow L., et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diab 2006; 55: 3550–5
   PubMed Web of Science ®Google Scholar
• Clausen P., Jacobsen P., Rossing K., Jensen J. S., Parving H‐H., Feldt‐Rasmussen B. Plasma concentrations of VCAM‐1 and ICAM‐1 are elevated in patients with Type 1 diabetes mellitus with microalbuminuria and overt nephropathy. Diabetic Med 2000; 17: 644–9
   PubMed Web of Science ®Google Scholar
• Davis B. J., Forbes J. M., Thomas M. C., Jerums G., Burns W. C., Kawachi H., et al. Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia 2004; 47: 89–97
   PubMed Web of Science ®Google Scholar
• Mezzano S. A., Ruiz‐Ortega M., Egido J. Angiotensin II and renal fibrosis. Hypertension 2005; 38: 635–8
   Google Scholar
• Sharp P. S., Rainbow S., Mukherjee S. Serum levels of low molecular weight advanced glycation end products in diabetic subjects. Diabetic Med 2003; 20: 575–9
   PubMed Web of Science ®Google Scholar